… be reversed after aflibercept treatment based on changes in diabetic macular edema, HEs …
alleviation of leakage due to reperfusion in the non-perfusion area, but we cannot rule out the …

… with PDR treated with intravitreal 2.0 mg aflibercept either monthly or quarterly, showed
stability in the amount of non-perfusion in patients receiving monthly aflibercept and not in those …

… retinal non-perfusion (RNP) are a key pathologic feature of the vascular component of diabetic
retinopathy. … of Intravitreal Aflibercept Injection for Improvement of Retinal Nonperfusion in …

… , randomized RECOVERY (Intravitreal Aflibercept for Retinal Nonperfusion in
Proliferative Diabetic Retinopathy) trial was to evaluate the impact of intravitreal aflibercept (Eylea, …

… The thickness of multiple retinal sublayers appears to decrease … intravitreal aflibercept
for proliferative diabetic retinopathy despite an absence of a change in peripheral non-perfusion. …

… intravitreal aflibercept on retinal non-perfusion (RNP) in eyes with proliferative diabetic
retinopathy (PDR) with no macular … , p<0.001) at month 12 following intravitreal aflibercept. …

… Retinal non-perfusion (RNP) is fundamental to disease onset and progression in diabetic
retinopathy (DR). … Three studies utilised ranibizumab, 2 studies utilised aflibercept and 1 study …

… In the mechanistic substudy, we evaluated the changes induced by aflibercept on retinal
new vessels, capillary non-perfusion and retinal intravascular oxygen saturation. …

… = 35 eyes) of intravitreal aflibercept administered on postnatal … -related macular degeneration,
diabetic retinopathy, macular … in retinal non-perfusion at varying doses of aflibercept in the …

… -VEGF agents on the regression of retinal non-perfusion in patients with DR. Furthermore, …
In this study, initial treatment with 4-monthly intravitreal aflibercept injections was compared …